ETHAMOLIN SUMMARY
Ethamolin®
(Ethanolamine Oleate)
Injection, 5%
For Local Intravenous Use Only
ETHAMOLIN® (Ethanolamine Oleate) Injection is a mild sclerosing agent.
ETHAMOLIN Injection is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.
ETHAMOLIN is not indicated for the treatment of patients with esophageal varices that have not bled. There is no evidence that treatment of this population decreases the likelihood of bleeding.
Sclerotherapy with ETHAMOLIN has no beneficial effect upon portal hypertension, the cause of esophageal varices, so that recanalization and collateralization may occur, necessitating reinjection.
|
NEWS HIGHLIGHTS
Published Studies Related to Ethamolin (Ethanolamine)
Administration of a dietary supplement ( N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial. [2009.03]
Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE-EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people...
Administration of a dietary supplement ( N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial. [2008.07.01]
Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE-EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people...
Ototoxicity of triethanolamine polypeptide (cerumenex) in the chinchilla. [2008.03]
The use of earwax softeners and cerumenolytics to unblock the external auditory canal is increasing. Although reports on their effectiveness are available, data about their effect on hearing are limited. OBJECTIVE: To assess the effect of ototopic triethanolamine polypeptide oleate condensate 10% (Cerumenex) on hearing. STUDY DESIGN: Prospective, randomized, controlled trial in a chinchilla animal model... CONCLUSIONS: In the chinchilla, when a tympanic perforation is present, Cerumenex causes a reduction in DPOAE signal and damage to the cochlear hair cells. Caution should be observed when prescribing this agent if the status of the tympanic membrane is unknown. Furthermore, its use without medical prescription should be discouraged because of the risk of ototoxicity and severe inflammatory reaction.
Clinical Trials Related to Ethamolin (Ethanolamine)
L-MTP-PE Compassion Access for High-Risk Osteosarcoma [Recruiting]
Primary Objective:
- To collect information regarding the safety and tolerability of L-MTP-PE.
Secondary Objectives:
- To assess outcomes of patients who receive L-MTP-PE.
- To evaluate serum concentration-time profiles of free and total L-MTP-PE in 15-20
patients.
LEAN Project: Weight Loss and Appetite Suppression
The primary aim is to examine whether the intake of PhosphoLEAN is effective in aiding a
cohort of women in losing weight. Participants taking the supplement will have significantly
greater improvement in study outcomes than those taking the placebo.
Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma [Recruiting]
Study No. 001 about Budesonide/Formoterol use in ASthMA sponsored by Agenzia Italiana del
FArmaco (Italian Drug Agency) (AIFA-ASMA-BF-001) The aim of the study is to verify whether
asthma not controlled by low doses inhaled corticosteroids, thus in need for step up
therapy, can be equally controlled by guidelines recommended regular bid treatment with long
acting beta agonist/inhaled corticosteroid (ICS/LABA) combination or the symptom driven use
of an ICS/LABA combination in the absence of maintenance therapy. The study is designed to
be able to evaluate the non inferiority of regular placebo plus prn inhaled
budesonide/formoterol (experimental treatment) versus regular, twice daily 160/4. 5 mcg
inhaled budesonide/formoterol combination plus prn inhaled terbutaline (guidelines
recommended treatment).
A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis [Recruiting]
Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an
ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by
the vestibular system, which is rich in histamine receptors. Multiple studies have shown
its effectiveness in treatment of post-operative nausea and vomiting in children.
It is also used for treatment of vertigo in children. Furthermore, it has the potential to
be much more cost-effective than ondansetron, with an average cost of $0. 90 US per dose .
Its principal side effects are drowsiness, dizziness and anticholinergic symptoms.
Restlessness and insomnia have also been described in children. To date, there has been no
published data on the efficacy of dimenhydrinate in controlling emesis in children with
acute gastroenteritis.
RESEARCH QUESTION
Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less
vomiting episodes than children treated with placebo?
|
